IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment скачать в хорошем качестве

IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment

In the fourth part of this roundtable series, Drs. McDermott, Beckermann, and Albiges discuss the use of IO/IO and IO/TKI treatments and how they can affect next-line treatment if patients progress. In a roundtable focused on non-clear cell renal cell carcinoma, moderator Daniel Joyce, MD, of Vanderbilt University Medical Center, led panelists David McDermott, MD, of Beth Israel Deaconess Medical Center; Katy Beckermann, MD, PhD, of Vanderbilt University Medical Center; and Laurence Albiges, MD, PhD, of Institut Gustave Roussy in a discussion on the management of differing disease states, new approaches such as IO/TKI and PD-L1, novel trials, and adjuvant treatments.